Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9NSD9

UPID:
SYFB_HUMAN

ALTERNATIVE NAMES:
Phenylalanyl-tRNA synthetase beta subunit

ALTERNATIVE UPACC:
Q9NSD9; B4DFM0; O95708; Q4ZFX1; Q57ZJ5; Q9NZZ6

BACKGROUND:
The Phenylalanyl-tRNA synthetase beta subunit, identified by the accession number Q9NSD9, is integral to the protein biosynthesis pathway. It specifically catalyzes the attachment of phenylalanine to its tRNA, a critical step in translating genetic information into functional proteins. This enzyme's activity ensures the fidelity of protein synthesis, crucial for cellular function and organismal development.

THERAPEUTIC SIGNIFICANCE:
The therapeutic significance of the Phenylalanine--tRNA ligase beta subunit is underscored by its association with Rajab interstitial lung disease with brain calcifications 1. This connection suggests that interventions targeting this protein's function could provide novel treatment options for patients suffering from this rare but severe genetic disorder. Exploring this protein's biology could unveil innovative therapeutic targets.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.